Delving into the Latest Updates on Pure Technologies Ltd. with Synapse

Overview

Tags

Other Diseases

Respiratory Diseases

Nervous System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

IL-6 x TGF-β x TNF-α	1
GABAA receptor(Gamma-aminobutyric acid A receptor)	1

A Phase 1, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of LYT-300 in Healthy Volunteers, and a Phase 1b/2a Study Part to Assess Effects of a Single Dose of LYT-300 vs. Placebo on the Response to a Standardized Behavioural Challenge in Healthy Volunteers

Part 1 is a single ascending dose (SAD) trial in healthy volunteers (HV) to assess the safety, tolerability, and pharmacokinetic (PK) profile of orally administered LYT-300.
Part 2 is a crossover assessment in HV of the effects of food on the safety, tolerability, and PK profile of orally administered LYT-300.
Part 3 is a multiple ascending dose (MAD) trial in HV to assess the safety, tolerability, and PK profile of multiple doses (up to 7 days) of orally administered LYT-300.
Part 4 is an assessment of the effects of LYT-300 vs. placebo on pharmacodynamic and patient reported outcome response to a validated clinical model of anxiety.

Start Date07 Dec 2021

Sponsor / Collaborator

Pure Technologies Ltd.

[+1]

NCT04652518

/ TerminatedPhase 2

A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease

This study is being conducted in two parts, A and B. Part A is a randomized, double-blind, parallel arm study to evaluate the safety and efficacy of LYT-100 compared to placebo in adults with post-acute COVID-19 respiratory complications. Part B is an Open Label Extension (OLE) study for patients who complete Part A.

Start Date11 Dec 2020

Sponsor / Collaborator

Pure Technologies Ltd.

[+2]

100 Clinical Results associated with Pure Technologies Ltd.

Login to view more data

0 Patents (Medical) associated with Pure Technologies Ltd.

Login to view more data

100 Deals associated with Pure Technologies Ltd.

Login to view more data

100 Translational Medicine associated with Pure Technologies Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 14 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Deupirfenidone ( IL-6 x TGF-β x TNF-α )	Idiopathic Pulmonary Fibrosis More	Phase 2
Brexanolone caprilcerbate ( GABAA receptor )	Anxiety Disorders More	Phase 1/2